This site uses cookies to provide you with a more responsive and personalized service. By clicking "Accept," you agree to the use of cookies on this site. Please read our Cookie Policy and Privacy Policy for more information on the use of cookies on this website.

DOJOLVI (triheptanoin) Oral Liquid Dosing Calculator

For HCPs only

This calculator is designed to help Healthcare Professionals calculate dosing of DOJOLVI for their patients

Now listed on the Alberta Drug Benefit List (Special Authorization)

Now covered by the Non-Insured Health Benefits (NIHB) (Limited Use)

Please confirm the
details below to continue

Please enter a valid licence number.

Indication

DOJOLVI® (triheptanoin) is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).

Clinical Use

The safety and efficacy of DOJOLVI in pediatric patients have been established. Clinical studies of DOJOLVI did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.

Contraindications

Triheptanoin is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.

Most Serious Warnings and Precautions

  • Feeding tube dysfunction: Performance and functionality can degrade over time depending on usage and environmental conditions. Do not administer DOJOLVI in feeding tubes manufactured of polyvinyl chloride (PVC). Regularly monitor the feeding tube to ensure proper functioning and integrity.
  • Intestinal malabsorption in patients with pancreatic insufficiency: Low or absent pancreatic enzymes may reduce absorption of heptanoate leading to insufficient supplementation of medium-chain fatty acids. Avoid administration of DOJOLVI in patients with pancreatic insufficiency.

For More Information

Please consult the Product Monograph for more information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece.

This patient is:

For patients not currently taking a MCT product

Initiate DOJOLVI at a total daily dosage of approximately 10% DCI divided into at least four times per day and increase to the recommended total daily dosage of up to 35% DCI over a period of 2 to 3 weeks.

For patients switching from another MCT product

Discontinue use of MCT products before starting DOJOLVI.

Initiate DOJOLVI at the last tolerated daily dosage of MCT divided into at least four times per day. Increase the total daily dosage by approximately 5% DCI every 2 to 3 days until the target dosage of up to 35% DCI is achieved.

Product Monograph

As you enter inputs, the calculator will automatically generate outputs

Inputs

Kcal/day
* Daily caloric intake
%
Decrease Decrease doses/day

%

Decrease Decrease days
days
Increase per
titration:

% DCI
( mL)

Dojolvi Prescription (Titration)

Initial Total Daily Dose (mL):
mL
Doses/Day:
Intial mL per Dose:
mL
Increase by:
% DCI = mL
every:
days
until reaching target:
mL dose

Dojolvi Prescription (Maintenance)

Target Total Daily Dose (mL):
mL
Doses/Day:
mL per Dose:
mL
Total Duration from Initial
to Maintenance:

days

Days –

mL/day | doses/day | mL/dose

Days +

mL/day | doses/day | mL/dose

NOTE: mL/day increase increments may not be exact due to rounding